Should You Be Investing In Marijuana

Matt Thalman - Contributor - ETFs

In April the world's first Marijuana Exchange Traded Fund, Horizon Medical Marijuana Life Sciences ETF (TSE:HMMJ) hit the public markets. The ETF went public at $10 per share and popped during its first few days of trading.

When HMMJ hit the public markets, investors were craving exposure to marijuana stocks as new laws and regulations have helped push marijuana into the mainstream spotlight. Some U.S. states and parts of Canada have decriminalized the drug while it has spread in popularity and acceptance for its medical use.


HMMJ has traded as high as $23 per share since going public, but currently, it is below its Initial Public Offering price, trading at $9.36 per share. So what is happening and is it worth investing in the industry today? Continue reading "Should You Be Investing In Marijuana"

Cannabis Cancer Stock Up 207% In 2017

Analysis originally distributed on July 19, 2017 By: Michael Vodicka of Cannabis Stock Trades

Cannabis is a proven treatment for cancer patients struggling with the side effects of chemotherapy such as nausea and loss of appetite.

But now, pre clinical research is showing that cannabis could actually be a cancer killer.

A group of scientists recently reported that THC and CBD slowed the growth and even killed certain cancer cells – including breast, brain and liver cancer – when grown in a lab.

Animal studies also suggest that cannabis could be a cancer killer.

A study conducted by Complutense University, one of the oldest and largest universities in Europe located in Madrid, showed that an injection of a synthetic THC eliminated malignant brain tumors in 1/3 of the rats studied while extending the life of another 1/3. Continue reading "Cannabis Cancer Stock Up 207% In 2017"

A 2nd Cannabis Stock With $1 Billion Drug Potential

Analysis originally distributed on June 7, 2017 By: Michael Vodicka of Cannabis Stock Trades

Blockbuster drugs are the holy grail of the pharmaceutical and biotech industry.

When annual sales of a new drug break the $1 billion mark, investors are usually rewarded with big gains.

This is what began happening late 2012 with Gilead Science (NASDAQ:GILD).

In 2013 the FDA approved Gilead's hepatitis C drug Sovaldi.

Then, in 2014, Gilead scored an FDA approval for another Hep C drug, Harvoni.

Both drugs went on to quickly hit blockbuster status - sending shares of Gilead soaring - jumping more than 200% in the next two years. Take a look below.

Image courtesy of

Today, the young cannabis industry is in hot pursuit of its first ever cannabis blockbuster - and I expect the winner of this race to deliver huge gains to shareholders. Continue reading "A 2nd Cannabis Stock With $1 Billion Drug Potential"